The effects of benoxaprofen on mononuclear and polymorphonuclear leucocyte motility. An in vitro and in vivo study.
Benoxaprofen at concentrations well within the normal therapeutic range was found to cause significant inhibition of both mononuclear leucocyte (MNL) and polymorphonuclear leucocyte (PMNL) motility in vitro. The ingestion of benoxaprofen 600 mg also resulted in a significant reduction of MNL migration, while co-incubation of control PMNLs with 25% heat-inactivated serum from healthy subjects resulted in a very significant inhibition of PMNL motility. Serum IgG levels also dropped significantly after benoxaprofen ingestion. These results show that human PMNL and MNL migration is significantly suppressed by benoxaprofen both in vitro and in vivo and that the anti-inflammatory activity of the drug is mediated at least partly by inhibition of the migration of both the cell types and suppression of immunoglobulin production, possibly by induction of suppressor MNL activity.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002465:Cell Movement; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003165:Complement System Proteins / Q000032:analysis; D006600:Hexosephosphates / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007962:Leukocytes / Q000187:drug effects*; D009504:Neutrophils / Q000187:drug effects*; D009195:Peroxidase / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D011422:Propionates / Q000097:blood / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006600:Hexosephosphates; D007136:Immunoglobulins; D011422:Propionates; C011677:benoxaprofen; D003165:Complement System Proteins; D009195:Peroxidase